Zeltiq Aesthetics Inc. Expected to Post Q4 2016 Earnings of $0.16 Per Share (ZLTQ)
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) – Stock analysts at Griffin Securities decreased their Q4 2016 earnings per share estimates for shares of Zeltiq Aesthetics in a note issued to investors on Tuesday. Griffin Securities analyst Z. Ajzenman now expects that the firm will post earnings per share of $0.16 for the quarter, down from their prior estimate of $0.17. Griffin Securities also issued estimates for Zeltiq Aesthetics’ Q2 2017 earnings at $0.04 EPS and Q3 2017 earnings at $0.28 EPS.
Other research analysts have also issued research reports about the stock. Northcoast Research reaffirmed a “buy” rating on shares of Zeltiq Aesthetics in a research note on Tuesday, November 8th. Canaccord Genuity lifted their price objective on shares of Zeltiq Aesthetics from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, November 10th. Zacks Investment Research raised shares of Zeltiq Aesthetics from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research note on Wednesday, October 26th. Brean Capital reissued a “buy” rating on shares of Zeltiq Aesthetics in a research note on Monday, October 24th. Finally, Stifel Nicolaus lifted their price objective on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, September 21st. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Zeltiq Aesthetics has a consensus rating of “Buy” and a consensus target price of $42.78.
Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 42.77 on Wednesday. The company has a market capitalization of $1.71 billion, a P/E ratio of 55.19 and a beta of 0.89. Zeltiq Aesthetics has a 52-week low of $18.41 and a 52-week high of $43.00. The firm has a 50-day moving average of $37.80 and a 200 day moving average of $33.69.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last posted its earnings results on Wednesday, November 9th. The company reported $0.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.04. The company earned $95.20 million during the quarter, compared to the consensus estimate of $90.84 million. Zeltiq Aesthetics had a net margin of 9.48% and a negative return on equity of 6.45%. The company’s revenue for the quarter was up 55.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 earnings per share.
A number of hedge funds have recently made changes to their positions in ZLTQ. FMR LLC increased its stake in Zeltiq Aesthetics by 45.2% in the second quarter. FMR LLC now owns 4,277,811 shares of the company’s stock worth $116,913,000 after buying an additional 1,332,129 shares during the period. Alliancebernstein L.P. increased its stake in Zeltiq Aesthetics by 2,184.0% in the second quarter. Alliancebernstein L.P. now owns 1,164,819 shares of the company’s stock worth $31,835,000 after buying an additional 1,113,819 shares during the period. Deerfield Management Co. acquired a new stake in Zeltiq Aesthetics during the first quarter worth about $29,996,000. Samlyn Capital LLC acquired a new stake in Zeltiq Aesthetics during the first quarter worth about $29,100,000. Finally, Victory Capital Management Inc. acquired a new stake in Zeltiq Aesthetics during the third quarter worth about $32,088,000.
In other Zeltiq Aesthetics news, insider Keith J. Sullivan sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $38.36, for a total transaction of $306,880.00. Following the sale, the insider now directly owns 83,159 shares in the company, valued at approximately $3,189,979.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Bradley Hauser sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $37.33, for a total transaction of $111,990.00. Following the sale, the vice president now owns 46,240 shares in the company, valued at $1,726,139.20. The disclosure for this sale can be found here. Company insiders own 15.60% of the company’s stock.
Zeltiq Aesthetics Company Profile
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.